{"entity":{"id":"naveris","kind":"company","name":"Naveris","aka":[],"tldr":"Naveris makes NavDx, a blood test that tracks DNA from the HPV virus shed by tumours, so doctors can confirm HPV-related throat and anal cancers and catch them coming back after treatment. It was bought by CareDx in 2026.","summary":"Naveris, based in Waltham, Massachusetts and founded in 2017, developed NavDx, a blood test that quantifies tumour tissue modified viral (TTMV) HPV DNA in plasma. The tumour-naive assay can confirm HPV-driven disease at diagnosis, assess treatment response and detect molecular residual disease (MRD) and recurrence in HPV-positive oropharyngeal and anal squamous cell carcinoma. The test runs in a CLIA-certified, CAP-accredited, New York State-approved laboratory. Medicare coverage began in 2023 with ADLT status at $1,800 per test; more than 130,000 commercial tests have been reported. Naveris raised an expanded Series A of $19 million in 2020 and $51 million in 2022, led by Gurnet Point Capital. CareDx agreed in April 2026 to acquire it for $160 million up front plus up to $100 million in milestones, closing in July 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://naveris.com/"},{"label":"CareDx 8-K exhibit: agreement to acquire Naveris (Apr 2026)","url":"https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm"},{"label":"CareDx completes acquisition (Jul 2026)","url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/naveris-pressrelease.htm"},{"label":"$51 million financing (Sep 2022)","url":"https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":["diagnostics"],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["2022 release dateline is Natick, MA; the current website gives Waltham, MA. Anal cancer has no id in the cancer list. NavDx is a laboratory developed test; no FDA clearance is claimed here."],"hq":"Waltham, MA","country":"US","companyType":"diagnostics","website":"https://naveris.com/","founded":2017,"stage":"acquired","investors":["acs-brightedge"],"funding":[{"round":"Series A","year":2020,"amountUsd":19000000,"source":"https://naveris.com/naveris-inc-raises-19-million-in-financing-to-advance-and-commercialize-blood-tests-for-early-detection-of-hpv-and-other-viral-related-cancers-i/","note":"Expanded Series A led by Gurnet Point Capital, December 2020."},{"round":"Series A","year":2022,"amountUsd":51000000,"source":"https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/","note":"$33.4 million Series A expansion bringing the round to $51 million; led by Gurnet Point Capital with TechU Ventures and BrightEdge, September 2022."},{"round":"Acquisition","year":2026,"amountUsd":160000000,"source":"https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm","note":"CareDx agreed to pay $160 million cash up front plus up to $100 million in revenue milestones (announced 28 April 2026); completion announced July 2026."}]},"route":"/companies/naveris/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/"}]}}